Elevai Labs, Common Stock (ELAB) Stock

$1.91 0.06 (3.26%)
Market Cap: $5.87M | NASDAQ

Elevai Labs, Common Stock Chart


Company Profile

Price: $1.91

Market Cap: $5.87M

Exchange: NASDAQ

CEO: Mr. Graydon Bensler C.F.A.

Sector: Healthcare

Industry: Biotechnology

Employees: -0.00B

Headquarters: None, None

Business Summary

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Elevai Labs, Common Stock News

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio

News image

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fir

News image

Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), a diversified holding company, for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024.

News image

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024.

News image

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

News image

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare Inc. (“Elevai”) pursuant to a definitive purchase agreement with Carmell Corporation (“Carmell”) (the “Divestiture”) and reaffirms its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare.

News image

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants. Northstrive Biosciences Inc., formerly Elevai Biosciences, Inc., is a biopharmaceutical company targeting obesity with next-generation treatments.

News image

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare.

News image

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

Carmell and PMGC Holdings Inc Announce Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair

News image

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization.

News image

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.

News image

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System. Root Renewal System Features Exclusive Technologies and Science-Driven Formulations.

News image

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024.

News image

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock.

News image

CORRECTION - Elevai Labs Inc.

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated.

News image

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation.

News image

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.

News image

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments.

News image

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl

News image

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.

News image

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,

News image

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,

News image

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic

News image

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the “Offering”) of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the “Company”), a pioneering force in medical aesthetics.

News image

Dow Gains Over 50 Points; Elevai Labs Shares Plummet

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 50 points on Monday.

News image

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

News image

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months.

News image

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary

News image

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria

News image

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.

News image

Elevai Labs, Common Stock Earnings

This section highlights Elevai Labs, Common Stock's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date:
Time:
Est. EPS: $-
Status: Unconfirmed

Last Earnings Results

Date: November 13, 2024
EPS: $-14.00
Est. EPS: $-
Revenue: $527.48K

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS

Financial Statements

Access annual & quarterly financial statements for Elevai Labs, Common Stock, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $1.71M $766.28K $-0.00B $-
Cost of Revenue $578.01K $324.00K $2.85K $-
Gross Profit $1.13M $442.27K $-2.02K $-
Gross Profit Ratio 66.25% 57.72% -244.01% 0.00%
Research and Development Expenses $426.24K $228.75K $123.63K $118.86K
General and Administrative Expenses $3.37M $1.54M $602.73K $95.94K
Selling and Marketing Expenses $660.29K $192.86K $31.61K $6.08K
Selling General and Administrative Expenses $4.03M $1.80M $633.96K $102.99K
Other Expenses $-3.32M $-198.44K $-25.45K $-
Operating Expenses $1.13M $2.23M $783.04K $222.91K
Cost and Expenses $5.47M $2.55M $785.89K $222.91K
Interest Income $5.56K $7.70K $- $-
Interest Expense $19.52K $2.63K $- $-
Depreciation and Amortization $11.65K $6.51K $2.76K $221.84K
EBITDA $-4.27M $-1.78M $-782.30K $-1.07K
EBITDA Ratio -249.35% -232.52% -94594.92% 0.00%
Operating Income $-3.67M $-1.79M $-785.06K $-221.84K
Operating Income Ratio -214.24% -233.37% -94928.66% 0.00%
Total Other Income Expenses Net $-632.45K $-11.98K $-0.00B $-1.07K
Income Before Tax $-4.30M $-1.80M $-784.74K $-222.91K
Income Before Tax Ratio -251.17% -234.94% -94889.84% 0.00%
Income Tax Expense $- $--0.00B $-0.00B $-1.07K
Net Income $-4.30M $-1.80M $-784.74K $-222.91K
Net Income Ratio -251.17% -234.94% -94889.84% 0.00%
EPS $-0.40 $-0.19 $-0.05 $-0.05
EPS Diluted $-0.40 $-0.19 $-0.05 $-0.05
Weighted Average Shares Outstanding 10.75M 9.53M 17.33M 4.41M
Weighted Average Shares Outstanding Diluted 10.75M 9.53M 17.33M 4.41M
SEC Filing Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022
Revenue $527.48K $605.53K $614.56K $698.59K $554.65K $316.53K $142.82K $138.90K $432.12K
Cost of Revenue $133.58K $166.28K $189.24K $239.36K $190.95K $108.18K $44.43K $47.20K $196.06K
Gross Profit $393.90K $439.25K $425.32K $459.23K $363.71K $208.35K $98.39K $91.70K $236.06K
Gross Profit Ratio 74.68% 72.54% 69.21% 65.74% 65.57% 65.82% 68.89% 66.02% 54.63%
Research and Development Expenses $95.26K $52.38K $103.19K $122.47K $86.37K $133.65K $83.74K $60.86K $89.33K
General and Administrative Expenses $1.04M $1.01M $1.45M $971.89K $891.36K $848.61K $655.82K $549.97K $471.45K
Selling and Marketing Expenses $94.51K $721.49K $393.04K $343.86K $99.71K $114.05K $102.68K $58.10K $73.27K
Selling General and Administrative Expenses $1.13M $1.73M $1.95M $1.32M $1.00M $962.66K $758.50K $653.66K $563.15K
Other Expenses $-835.03K $66.21K $-59.11K $-89.15K $-65.83K $- $- $-49.95K $-55.89K
Operating Expenses $393.90K $1.85M $2.11M $1.53M $1.15M $1.26M $944.52K $764.47K $708.36K
Cost and Expenses $527.48K $2.01M $2.30M $1.77M $1.34M $1.37M $988.95K $811.66K $904.42K
Interest Income $-0.00B $-0.00B $-0.00B $-0.00B $-0.00B $-0.00B $5.11K $4.46K $3.16K
Interest Expense $648.33K $30.81K $23.54K $6.77K $5.71K $4.41K $2.64K $-0.00B $-0.00B
Depreciation and Amortization $-36.24K $24.77K $21.19K $2.91K $2.44K $2.91K $2.91K $2.61K $1.63K
EBITDA $-850.24K $-1.36M $-1.35M $-1.07M $-776.65K $-1.05M $-838.11K $-670.16K $-470.67K
EBITDA Ratio -161.19% -224.09% -270.39% -153.37% -141.75% -330.99% -586.83% -482.48% -108.92%
Operating Income $- $-1.41M $-1.68M $-1.07M $-788.66K $-1.05M $-841.02K $-672.77K $-472.30K
Operating Income Ratio 0.00% -232.59% -273.84% -153.79% -142.19% -331.91% -588.87% -484.36% -109.30%
Total Other Income Expenses Net $-1.50M $-4.12K $285.67K $-83.58K $5.62K $-228.90K $-234.57K $-21.68K $-26.78K
Income Before Tax $-1.50M $-1.41M $-1.40M $-1.16M $-783.05K $-1.28M $-1.08M $-652.66K $-499.08K
Income Before Tax Ratio -284.61% -233.27% -227.36% -165.75% -141.18% -404.34% -756.68% -469.88% -115.50%
Income Tax Expense $- $- $-0.00B $--0.00B $-0.00B $4.41K $2.64K $--0.00B $-25.45K
Net Income $-1.50M $-1.41M $-1.40M $-1.16M $-783.05K $-1.28M $-1.08M $-652.66K $-499.08K
Net Income Ratio -284.61% -233.27% -227.36% -165.75% -141.18% -404.34% -756.68% -469.88% -115.50%
EPS $-0.07 $-0.08 $-0.08 $-0.07 $-0.05 $-0.07 $-0.11 $-0.07 $-0.03
EPS Diluted $-0.07 $-0.08 $-0.08 $-0.07 $-0.05 $-0.07 $-0.06 $-0.07 $-0.03
Weighted Average Shares Outstanding 22.16M 18.30M 17.33M 17.33M 17.33M 17.33M 9.71M 9.57M 17.33M
Weighted Average Shares Outstanding Diluted 22.16M 18.30M 17.33M 17.33M 17.33M 17.33M 17.33M 9.57M 17.33M
SEC Filing Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $3.33M $1.15M $411.86K $13.35K
Short Term Investments $- $- $- $-
Cash and Short Term Investments $3.33M $1.15M $411.86K $13.35K
Net Receivables $36.16K $12.85K $1.71K $-
Inventory $495.67K $243.75K $191.78K $-
Other Current Assets $1.06M $153.42K $62.14K $3.67K
Total Current Assets $4.92M $1.50M $636.52K $17.02K
Property Plant Equipment Net $259.70K $330.09K $29.73K $-
Goodwill $- $- $- $-
Intangible Assets $- $- $- $-
Goodwill and Intangible Assets $- $- $- $-
Long Term Investments $- $10.77K $- $-
Tax Assets $- $- $- $-
Other Non-Current Assets $10.77K $50.00K $- $-
Total Non-Current Assets $270.47K $390.86K $29.73K $-
Other Assets $- $-0.00B $- $-
Total Assets $5.19M $1.89M $666.25K $17.02K
Account Payables $596.15K $210.84K $98.17K $-0.00B
Short Term Debt $145.00K $110.62K $- $24.00K
Tax Payables $- $- $- $-
Deferred Revenue $36.69K $10.17K $- $-
Other Current Liabilities $519.51K $256.64K $117.45K $16.46K
Total Current Liabilities $1.30M $588.27K $215.62K $40.61K
Long Term Debt $65.49K $172.60K $- $-
Deferred Revenue Non-Current $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $-
Other Non-Current Liabilities $- $- $- $-
Total Non-Current Liabilities $65.49K $172.60K $- $-
Other Liabilities $- $- $- $-
Total Liabilities $1.36M $760.87K $215.62K $40.61K
Preferred Stock $- $-0.00B $-0.00B $-0.00B
Common Stock $1.73K $-0.00B $-0.00B $-0.00B
Retained Earnings $-7.02M $-2.72M $-922.11K $-137.37K
Accumulated Other Comprehensive Income Loss $-0.00B $-0.00B $-0.00B $-1.22K
Other Total Stockholders Equity $10.85M $3.85M $1.37M $114.13K
Total Stockholders Equity $3.83M $1.13M $450.63K $-23.59K
Total Equity $3.83M $1.13M $450.63K $-23.59K
Total Liabilities and Stockholders Equity $5.19M $1.89M $666.25K $17.02K
Minority Interest $- $- $- $-
Total Liabilities and Total Equity $5.19M $1.89M $666.25K $17.02K
Total Investments $10.77K $10.77K $- $-
Total Debt $210.49K $283.22K $- $24.00K
Net Debt $-3.12M $-871.68K $-411.86K $10.65K


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 December 31, 2022 September 30, 2022
Cash and Cash Equivalents $6.43M $100.03K $943.80K $3.33M $476.86K $601.26K $1.15M $1.15M
Short Term Investments $- $- $- $- $- $- $- $-
Cash and Short Term Investments $6.43M $100.03K $943.80K $3.33M $476.86K $601.26K $1.15M $1.15M
Net Receivables $27.89K $29.07K $54.20K $36.16K $8.38K $34.44K $12.85K $12.85K
Inventory $986.42K $978.55K $945.06K $598.79K $510.15K $477.86K $243.75K $243.75K
Other Current Assets $787.85K $923.44K $1.20M $1.06M $292.06K $336.94K $153.42K $89.82K
Total Current Assets $8.23M $2.03M $3.14M $4.92M $1.04M $1.45M $1.50M $1.50M
Property Plant Equipment Net $154.00K $193.29K $231.56K $259.70K $295.61K $282.68K $330.09K $330.09K
Goodwill $- $- $- $- $- $- $- $-
Intangible Assets $2.82M $2.85M $843.50K $- $- $- $- $-
Goodwill and Intangible Assets $2.82M $2.85M $843.50K $- $- $- $- $-
Long Term Investments $- $10.77K $10.77K $10.77K $10.77K $- $10.77K $10.77K
Tax Assets $- $- $- $- $- $- $- $-
Other Non-Current Assets $- $- $--0.00B $--0.00B $236.94K $10.77K $50.00K $50.00K
Total Non-Current Assets $2.98M $3.05M $1.09M $270.47K $543.33K $293.45K $390.86K $390.86K
Other Assets $- $- $-0.00B $-0.00B $-0.00B $- $-0.00B $-0.00B
Total Assets $11.21M $5.08M $4.23M $5.19M $1.58M $1.74M $1.89M $1.89M
Account Payables $1.08M $1.14M $395.25K $596.15K $573.05K $537.60K $210.84K $222.46K
Short Term Debt $103.31K $140.06K $149.21K $145.00K $140.91K $115.11K $110.62K $110.62K
Tax Payables $- $- $- $- $- $- $- $-
Deferred Revenue $39.58K $24.31K $35.15K $36.69K $54.85K $85.37K $10.17K $-
Other Current Liabilities $908.91K $630.21K $642.52K $519.51K $874.76K $824.69K $256.64K $255.19K
Total Current Liabilities $2.13M $1.94M $1.22M $1.30M $1.64M $1.56M $588.27K $588.27K
Long Term Debt $- $- $26.57K $65.49K $103.31K $113.90K $172.60K $-
Deferred Revenue Non-Current $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $- $- $- $-
Other Non-Current Liabilities $519.71K $505.36K $491.56K $- $- $- $- $-
Total Non-Current Liabilities $519.71K $505.36K $518.13K $65.49K $103.31K $113.90K $172.60K $172.60K
Other Liabilities $- $-0.00B $- $- $- $- $- $-
Total Liabilities $2.65M $2.44M $1.74M $1.36M $1.75M $1.68M $760.87K $760.87K
Preferred Stock $- $- $- $- $-0.00B $-0.00B $-0.00B $-0.00B
Common Stock $4.94K $1.89K $1.73K $1.73K $1.01K $-0.00B $-0.00B $-0.00B
Retained Earnings $-11.33M $-9.83M $-8.42M $-7.02M $-5.87M $-5.08M $-2.72M $-2.72M
Accumulated Other Comprehensive Income Loss $-0.00B $1.24K $1.38K $-0.00B $-0.00B $-0.00B $-0.00B $-0.00B
Other Total Stockholders Equity $19.88M $12.47M $10.90M $10.85M $5.70M $5.15M $3.85M $3.85M
Total Stockholders Equity $8.56M $2.64M $2.49M $3.83M $-163.90K $67.29K $1.13M $1.13M
Total Equity $8.56M $2.64M $2.49M $3.83M $-163.90K $67.29K $1.13M $1.13M
Total Liabilities and Stockholders Equity $11.21M $5.08M $4.23M $5.19M $1.58M $1.74M $1.89M $1.89M
Minority Interest $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $11.21M $5.08M $4.23M $5.19M $1.58M $1.74M $1.89M $1.89M
Total Investments $- $10.77K $10.77K $10.77K $10.77K $- $10.77K $10.77K
Total Debt $103.31K $140.06K $175.78K $210.49K $244.22K $229.01K $283.22K $283.22K
Net Debt $-6.32M $40.03K $-768.02K $-3.12M $-232.64K $-372.25K $-871.68K $-871.68K

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-4.30M $-1.80M $-784.74K $-222.91K
Depreciation and Amortization $11.65K $6.51K $2.76K $-
Deferred Income Tax $- $- $- $-
Stock Based Compensation $487.74K $171.87K $142.35K $-
Change in Working Capital $-823.19K $12.43K $-21.91K $6.79K
Accounts Receivables $-23.22K $-11.55K $-1.35K $--0.00B
Inventory $-265.52K $-69.33K $-160.82K $-
Accounts Payables $466.89K $65.19K $192.09K $-
Other Working Capital $-1.00M $28.12K $-51.82K $7.39K
Other Non Cash Items $68.51K $224.16K $118.56K $-1.04K
Net Cash Provided by Operating Activities $-4.56M $-1.59M $-660.93K $-217.16K
Investments in Property Plant and Equipment $-11.19K $-35.53K $-32.48K $-
Acquisitions Net $- $3.50K $- $-
Purchases of Investments $- $- $- $-
Sales Maturities of Investments $- $- $- $-
Other Investing Activities $- $3.50K $- $-
Net Cash Used for Investing Activities $-11.19K $-32.03K $-32.48K $-
Debt Repayment $- $183.97K $- $-
Common Stock Issued $7.46M $2.18M $1.09M $-
Common Stock Repurchased $- $- $- $-
Dividends Paid $- $- $- $-
Other Financing Activities $-724.70K $2.18M $1.09M $238.28K
Net Cash Used Provided by Financing Activities $6.74M $2.36M $1.09M $238.28K
Effect of Forex Changes on Cash $1.06K $-1.31K $1.35K $-1.51K
Net Change in Cash $2.17M $743.04K $398.51K $19.61K
Cash at End of Period $3.33M $1.15M $411.86K $19.61K
Cash at Beginning of Period $1.15M $411.86K $13.35K $-
Operating Cash Flow $-4.56M $-1.59M $-660.93K $-217.16K
Capital Expenditure $-11.19K $-35.53K $-32.48K $-
Free Cash Flow $-4.57M $-1.62M $-693.41K $-217.16K

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022
Net Income $-1.50M $-1.41M $-1.40M $-1.16M $-783.05K $-1.28M $-1.08M $-652.66K $-499.08K
Depreciation and Amortization $-36.24K $24.77K $21.19K $2.91K $2.91K $2.91K $2.91K $2.61K $1.70K
Deferred Income Tax $- $- $- $- $- $- $- $- $-
Stock Based Compensation $47.04K $-44.85K $55.34K $141.19K $161.48K $109.91K $75.16K $77.77K $35.59K
Change in Working Capital $484.67K $656.12K $-746.71K $-993.86K $113.14K $176.50K $-118.97K $83.57K $-146.43K
Accounts Receivables $1.31K $25.08K $-18.12K $-27.73K $25.99K $11.77K $-33.25K $2.26K $-11.57K
Inventory $-7.87K $-33.48K $-449.40K $3.64K $-21.45K $-164.35K $-83.36K $-49.46K $31.57K
Accounts Payables $173.01K $350.81K $-140.70K $17.61K $74.23K $244.57K $130.48K $71.02K $-
Other Working Capital $318.22K $313.72K $-138.50K $-987.39K $-30.51K $15.63K $59.56K $59.74K $-166.43K
Other Non Cash Items $624.12K $-4.24K $449.29K $-226.99K $--0.00B $--0.00B $--0.00B $41.47K $18.08K
Net Cash Provided by Operating Activities $-381.68K $-780.69K $-2.32M $-2.39M $-514.40K $-768.76K $-885.51K $-506.40K $-590.14K
Investments in Property Plant and Equipment $-50.00K $- $-59.16K $- $- $- $-11.19K $1.40K $-29.99K
Acquisitions Net $- $- $- $- $- $- $- $- $-
Purchases of Investments $- $- $- $- $- $- $- $- $-
Sales Maturities of Investments $- $- $- $- $- $- $- $- $-
Other Investing Activities $- $-62.32K $-50.00K $- $- $- $- $- $-
Net Cash Used for Investing Activities $-50.00K $-62.32K $-59.16K $- $- $- $-11.19K $1.40K $-29.99K
Debt Repayment $- $- $- $- $- $- $- $- $-1.98K
Common Stock Issued $6.99M $- $- $6.00M $390.00K $323.59K $750.00K $122.10K $1.81M
Common Stock Repurchased $- $- $- $- $- $- $- $-2.07M $-
Dividends Paid $- $- $- $- $- $- $- $- $-
Other Financing Activities $-235.56K $- $- $-762.20K $- $- $37.50K $87.10K $-
Net Cash Used Provided by Financing Activities $6.76M $- $- $5.24M $390.00K $323.59K $787.50K $87.10K $1.80M
Effect of Forex Changes on Cash $--0.00B $--0.00B $-0.00B $-0.00B $--0.00B $-0.00B $-0.00B $--0.00B $-1.08K
Net Change in Cash $6.33M $-843.76K $-2.38M $2.85M $-124.41K $-444.58K $-109.06K $- $1.18M
Cash at End of Period $6.43M $100.03K $943.80K $3.33M $476.86K $601.26K $1.05M $1.15M $1.57M
Cash at Beginning of Period $100.03K $943.80K $3.33M $476.86K $601.26K $1.05M $1.15M $1.15M $389.98K
Operating Cash Flow $-381.68K $-780.69K $-2.32M $-2.39M $-514.40K $-768.76K $-885.51K $-506.40K $-590.14K
Capital Expenditure $-50.00K $-62.32K $-59.16K $- $- $- $-11.19K $1.40K $-29.99K
Free Cash Flow $-431.68K $-843.01K $-2.38M $-2.39M $-514.40K $-768.76K $-896.70K $-505.00K $-620.13K


No forecast data available for ELAB at this time.

Elevai Labs, Common Stock Dividends

Explore Elevai Labs, Common Stock's dividend history, including dividend yield, payout ratio, and historical payments.

Elevai Labs, Common Stock does not currently pay a dividend.

Peers: Biotechnology

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
Current Reports (8-K)
Ownership
Proxy Statements